Detection The Polymorphism in exon- 6 for gene PPAR-ᵧ in Obese Polycystic Ovarian Syndrome Women
Article Sidebar
Main Article Content
Abstract
Peroxisome Proliferator Activated Receptors Gamma (PPAR-ᵞ) is a nuclear transcription factor, which Protein receptors for insulin and have a significant role in insulin resistance and Type 2 Diabetes mellitus in addition to the role of the gene encoded in the differentiation Adipocyte and the development of Adipose tissue. at present research has been detected substitution silent mutation C T in the exon 6 of the gene PPAR-ᵧ in 111 women, including 73 obese women with Polycystic ovarian syndrome and 38 healthy women . in addition we determined certain biochemical variables (Blood Sugar, HDL-C, Triglycerides) and find a body mass index (BMI) and compared between the two groups of women where the results showed significant difference value of BMI and the concentration of each of the (Blood Sugar, HDL-C, Triglycerides) and at (0.05 and 0.01) among Patient women and Healthy the results showed significant difference in mutant T allele frequency between them . The value in Obese PCOS women was (0.336) compared to the value at the healthy women (0:29) this indicates the a correlation between substitution silent mutation C T in exon 6 for PPAR-ᵧ and disease
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1- Franks, S.( 1995). Polycystic ovary syndrome. N. Engl. J Med 333:853–861.
2- Carmina, E. and Lobo, R.A. (1999). Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin. Endocrinol Metab. 84:1897–1899.
3- Rosenbaum, M.; Leibel, R.L. and Hirsch, J. (1997). Obesity. N Engl J Med 337:396 –407.
4- Maeda, K.; Okubo, K.; Shimomura, I.; Mizuno, K. and Matsuzawa, K. (1997). Analysisof an expression profile of genes in the human adipose tissue. Gene 190:227–235.
5- Rocchi, S. and Auwerx, J. (2000). Peroxisome proliferator-activated receptor_, theultimate liaison between fat and transcription. Br. J. Nutr 84:223–227.
6- Sewter, C.;Blows, F.; Considine, R.; Vidal-Puig, A. and O’Rahilly, S. (2002). Differential effects of adiposity on peroxisomal proliferator-activated receptor_ 1 and _ messenger ribonucleic acid expression in human adipocytes. J Clin. Endocrinol. Metab 87:4203–4207.
7- Tamori, Y.; Masugi, J.; Nishino, N. and Kasuga, M.( 2002). Role of peroxisome proliferator-activated receptor_in maintenance of the characteristics of mature 3T3–L1 adipocytes.Diabetes. 51:2045–2055.
8- Fajas, L.; Auboeuf, D.; Raspe,´E. Schoonjans, K.; Lefebvre, A-M.; Saladin, R.; Najib,J.; Laville, M.; Fruchart, J-C.; Deeb, S.; Vidal-Puig, A. ;Flier, J.; Briggs, M.R.; Staels, B.;Vidal, H. and Auwerx, J. (1997) The organization, promoter analysis, and expression of the human PPAR_ gene. J Biol Chem 272:18779 –18789. 9- Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K. Gonzalez, F.J.; Grimaldi, P.A.; Kadowaki, T.; Lazar, M.A.; O'Rahilly, S.; Palmer, C.N. ; Plutzky, J.; Reddy, J.K.; Spiegelman, B.M. ; Staels, B. and Wahli, W. (2006). "International Union of Pharmacology. LXI. Peroxisome proliferator - activated receptors". Pharmacol. Rev. 58 (4): 726–741. 10- Belfiore, A.; Genua, M. and Malaguarnera, R. (2009). "PPAR-gamma Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer". PPARRes 2009:830501.doi:10.1155/2009/830501. PMC 2709717. PMID 19609453. 11- Feige, J.N.; Gelman, L.; Michalik ,L.; Desvergne, B. and Wahli, W. (2006). "From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions". Prog. Lipid Res. 45 (2): 120–159.
12- Berger, J. and Moller, D.E. (2002). "The mechanisms of action of PPARs". Annu. Rev. Med.53: 409–435.
13- Vidal-Puig, A.J.; Considine, R.V.; Jimenez-Linan, M.; Werman, A.; Pories, W.J.; Caro,F. and Flier, J.S. (1997). Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99:2416 –2422.
14- Tontonoz, P.; Hu, E.; Graves, R.A.; Budavari, A.I. and Spiegelman, B.M.( 1994). PPAR _2: tissue-specific regulator of an adipocyte enhancer. Gene. Dev. 8:1224 –1234.
15- Evans, D.; Mann, W.A.; de Heer, J.; Michel, U.; Wendt, D.; Kortner, B.; Wolf, A. and Beisiegel, U. (2000). Variation in the gene for human peroxisome proliferator activated receptor _ (PPAR_) does not play a major role in the development of morbid obesity. Int. J. Obes. 24:647–651.
16- Ristow, M.; Muller-Wieland, D.; Pfeiffer, A.; Krone, W. and Kahn, C.( 1998). Obesity associated with a mutation in a genetic regulator of adipocyte differentiation.N. Engl J. Med 339:953–959.
17- Valve, R.; Sivenius, K.; Miettinen, R.; Pihlajamaki; J.; Rissanen, A.; Deeb, S.S.; Auwerx, J.; Uusitupa, M. and Laakso, M. (1999). Two polymorphisms in the peroxisome proliferator-activated receptor_gene are associated with severe overweight among obese women. J. Clin. Endocrinol. Metab. 84:3708 –3712.
18- Hara, M.; Alcoser, S.Y.; Qaadir, A.; Beiswenger, K.; Cox, N.J. and Ehrmann, D.A. (2002). Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro12Ala polymorphism in the PPAR_ gene. J Clin Endocrinol Metab87:772–775
19- Meirhaeghe, A.; Fajas, L.; Helbecque, N.; Cottel, D.; Lebe,l.; Dallongeville, J.; Deeb, S.; Auwerx, J. and Amouyel, P.(1998). A genetic polymorphism of the peroxisome proliferator-
activated receptor _ gene influences plasma leptin levels in obesehumans. Hum. Mol. Genet. 7:435–440.
20- Fauser , B. C. (2004). Revised 2003 consensus on diagnostic criteria and long term healthy risks related to polycystic ovary syndrome (PCOS). Hum Reprod . 19(1): 41-47.
21- Bartlett, J.M. and White, A. (2007). Extraction of DNA from whole blood. Methods in Molecular. Biology.vol. 226: 29-33.
22- Sam, S.and Dunaif, A.(2003). Polycystic ovary syndrome: syndrome XX? Trends. Endocrinol Metab. 14:365–370.
23- Acie, P.; Francisco, Q.; Pilar, M.; Encarnacio, N. V. Jose, A. Lo, P.; Maribel, A.; Monserrat, M. and Rocio, A.(1999). Insulin, androgens, and obesity in women with and without polycystic ovary syndrome:a heterogeneous group of disorders. FERTILITY AND STERILITY . 72, ( 1):32-40.
24- Richard, S. and Legro, M.D.(2012). Obesity and PCOS: Implication for diagnosis and treatment. Siminars in Reproductive Medicine. 30: 496506.
25- Clark, A. M.; Ledger, W.; Galletly, C.; Tomlison, L.; Blaney, F.; Wang, X..(1995). Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. 10(10):2705-12.
26- Venkatesan, A.M.; Dunaif, A. and Corbould, A. (2001). Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog. Horm. Res.56:295–308.
27- Rangwala, S.M. and Lazar, M.A. (2004). Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends. Pharmacol. Sci. 25:331–336.
28- Legro , R.S.; Blanche, P.; Krauss, R.M. and Lobo, R.A. (1999). Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovay syndrome: influence of insulin and genetic factors. Fertil. Steril. 72: 990-5.
29- Diao, F.Y. ; Xu, M.; Hu,Y. ; Li, J.; Xu, Z.; Lin, M.; Wang, L.; Zhou, Y.; Zhou, Z.; Liu, J. and Sha, J. (2004). The molecular characteristics of polycystic ovary syndrome (PCOS). Ovary defined by human ovary cDNA microarray. J. Mol. Endocrinol. . 33: 59-72.
30- Orio, F. J.; Giuseppe, M.; Sebastiano, D.; Stefano, P.; Donato, L.; Veronica, S.; Silvia, S.; Fulvio,Z.; Annamaria, C. and Gaetano, L. (2003). Exon 6 and 2 Peroxisome Proliferator-Activated Receptor _ Polymorphisms in Polycystic Ovary Syndrome. Clin Endocrinology Metab . 88(12) : 5887-5892.
31- Takano, H. and Komuro, I.(2002). Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. J . Diabetes Complications .16:108 –14.
32- Altshuler, D.; Hirschhorn, J.N.; Klannemark, M.; Lindgren, C.M.; Vohl, M.C. and Nemesh, J. (2000). The common PPARgamma Pro12Ala polymorphism isassociated with decreased risk of type 2 diabetes. Nat. Genet. 26:76–80.